Viveve Medical, Inc. (NASDAQ:VIVE) has been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.

Brokers have set a 12-month consensus price objective of $13.60 for the company and are anticipating that the company will post ($0.48) earnings per share for the current quarter, according to Zacks. Zacks has also given Viveve Medical an industry rank of 151 out of 265 based on the ratings given to related companies.

Separately, B. Riley initiated coverage on shares of Viveve Medical in a research note on Monday, November 7th. They issued a “buy” rating and a $8.00 price target on the stock.

A hedge fund recently raised its stake in Viveve Medical stock. HighTower Advisors LLC raised its stake in shares of Viveve Medical, Inc. (NASDAQ:VIVE) by 39.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 910,632 shares of the company’s stock after buying an additional 259,861 shares during the period. HighTower Advisors LLC’s holdings in Viveve Medical were worth $6,574,000 at the end of the most recent quarter. 54.43% of the stock is currently owned by hedge funds and other institutional investors.

Viveve Medical (NASDAQ:VIVE) opened at 4.92 on Friday. Viveve Medical has a 52-week low of $4.02 and a 52-week high of $10.50. The company has a 50-day moving average of $5.00 and a 200 day moving average of $6.22.

This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of US and international trademark and copyright law. The original version of this news story can be viewed at

About Viveve Medical

Viveve Medical, Inc, formerly PLC Systems, Inc, designs, develops, manufactures and markets medical devices for the non-invasive treatment of vaginal laxity. The Company’s Viveve Treatment is a non-invasive solution for vaginal laxity that is performed in approximately 30 minutes, in a physician’s office.

5 Day Chart for NASDAQ:VIVE

Get a free copy of the Zacks research report on Viveve Medical (VIVE)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.